|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
CTRI |
|
Last refreshed on:
|
24 November 2021 |
|
Main ID: |
CTRI/2020/08/027225 |
|
Date of registration:
|
18-08-2020 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Ivermectin as a possible treatment for COVID-19
|
|
Scientific title:
|
Ivermectin as a potential treatment for COVID 19: A double blind randomized placebo-controlled trial |
|
Date of first enrolment:
|
28-08-2020 |
|
Target sample size:
|
90 |
|
Recruitment status: |
Completed |
|
URL:
|
http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46660 |
|
Study type:
|
Interventional |
|
Study design:
|
Randomized, Parallel Group, Placebo Controlled Trial
Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
India
| | | | | | | |
|
Contacts
|
|
Name:
|
Ravi Kirti
|
|
Address:
|
Department of General Medicine
1st Floor, OPD Building
AIIMS, Phulwari Sharif
Patna
801507
Patna, BIHAR
India |
|
Telephone:
|
9572424447 |
|
Email:
|
drravikirti@aiimspatna.org |
|
Affiliation:
|
All India Institute of Medical Sciences |
|
|
Name:
|
Ravi Kirti
|
|
Address:
|
Department of General Medicine, 1st Floor,OPD Building
AIIMS, Phulwari Sharif
Patna
801507
Patna, BIHAR
India |
|
Telephone:
|
9572424447 |
|
Email:
|
drravikirti@aiimspatna.org |
|
Affiliation:
|
All India Institute of Medical Sciences |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Patients admitted with COVID-19 with mild to moderate severity
Exclusion criteria: History of allergy to Ivermectin
Unwillingness to participate in the study
Age minimum:
Age maximum:
Gender:
|
|
Health Condition(s) or Problem(s) studied
|
|
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
|
|
Intervention(s)
|
Intervention1: Ivermectin: 12 mg orally to be administered once daily on days 1 and 2
Control Intervention1: Placebo tablets: A placebo tablet similar to Ivermectin 12 mg (provided by the manufacturer) to be given once daily on days 1 and 2.
|
|
Primary Outcome(s)
|
|
Negative RT-PCRTimepoint: Day 6
|
|
Secondary Outcome(s)
|
|
ICU AdmissionTimepoint: NA
|
|
Mechanical VentilationTimepoint: NA
|
|
In-hospital mortalityTimepoint: NA
|
|
Discharge by day 10Timepoint: Day 10
|
|
Source(s) of Monetary Support
|
|
All India Institute of Medical Sciences, Phulwari Sharif, Patna 801507
|
|
Ethics review
|
Status: Approved
Approval date: 11/08/2020
Contact:
AIIMS, Patna
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
31/10/2020 |
|
URL:
|
|
|
|